CONCORD

Concord Drugs Share Price

₹35.97 +0.23 (0.64%)

24 Nov, 2024 03:09

SIP TrendupStart SIP in CONCORD

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -0.91%
  • Over 3 Month + 0.25%
  • Over 6 Month -10.19%
  • Over 1 Year + 1.1%
SIP Lightning

Smart Investing Starts Here Start SIP with Concord Drugs for Steady Growth!

Invest Now

Concord Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Concord Drugs Financials

Concord Drugs Technicals

EMA & SMA

Current Price
₹35.97
+ 0.23 (0.64%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹36.60
  • 50 Day
  • ₹36.81
  • 100 Day
  • ₹37.11
  • 200 Day
  • ₹37.25

Resistance and Support

36.52 Pivot Speed
  • R3 39.23
  • R2 38.51
  • R1 37.24
  • S1 35.25
  • S2 34.53
  • S3 33.26

What's your outlook on Concord Drugs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,085.75 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 20% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results (Revised)
2024-02-13 Quarterly Results
2023-11-14 Quarterly Results

Concord Drugs F&O

Concord Drugs Shareholding Pattern

44.08%
4.97%
4.3%
8.1%
7.33%
31.22%

About Concord Drugs

  • NSE Symbol
  • CONCORD
  • BSE Symbol
  • 538965
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE858L01010

Similar Stocks to Concord Drugs

Concord Drugs FAQs

Concord Drugs share price is ₹35 As on 24 November, 2024 | 02:55

The Market Cap of Concord Drugs is ₹36 Cr As on 24 November, 2024 | 02:55

The P/E ratio of Concord Drugs is -70.6 As on 24 November, 2024 | 02:55

The PB ratio of Concord Drugs is 1.1 As on 24 November, 2024 | 02:55

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23